Inipharm Inc

Inipharm, Inc. develops biopharmaceutical therapies for severe liver diseases. The Company focuses on discovering and advancing small-molecule inhibitors targeting HSD17B13, and conducts clinical trials for liver disease treatments. Inipharm Inc serves patients with severe and fibrotic liver diseases, including MASH, in the United States.